Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

SOHO 2020 | Horizon scan of CAR-T for lymphoma

Sattva Neelapu • 9 Sep 2020
SOHO 2020
B-Cell Lymphoma Hodgkin Lymphoma Lymphoma ALLO-501 BiTEs CAR-T
ALPHA

Sattva S Neelapu, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of the current lymphoma treatment landscape of CAR T-cell therapies in lymphoma and highlights its benefits, including long-term remissions. Dr Neelapu also explores unmet needs in this area, including the development of allogeneic off-the-shelf CAR T-cell therapies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Sattva Neelapu

Five-year follow-up of the ZUMA-5 trial investigating axi-cel in R/R indolent NHL
4:50
Five-year follow-up of the ZUMA-5 trial investigating axi-cel in R/R indolent NHL
Sattva Neelapu • 12 Dec 2024
Next steps with ADI-001
0:42
Next steps with ADI-001
Sattva Neelapu • 5 Jun 2022
ZUMA-12: axi-cel as first-line therapy in high-risk large B-cell lymphoma
2:06
ZUMA-12: axi-cel as first-line therapy in high-risk large B-cell lymphoma
Sattva Neelapu • 5 Jun 2022
ADI-001: anti-CD20 CAR-engineered allogeneic γδ T cells in adults with B-cell malignancies
3:24
ADI-001: anti-CD20 CAR-engineered allogeneic γδ T cells in adults with B-cell malignancies
Sattva Neelapu • 5 Jun 2022

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals